Background: The impact of smoking at diagnosis and subsequent smoking cessation on clinical outcomes in Crohn's disease (CD) has not been evaluated in a population-based cohort.
IntroductIon
Smoking is a key modifiable environmental risk factor implicated in the onset of Crohn's disease (CD) [1] . Despite recent global reductions, approximately one in five British adults smoke currently [2] . Recent data from the UK indicates there may be a similar prevalence amongst patients with CD [3] , although in some CD populations smoking is much more frequent [4, 5] .
Tobacco exposure impacts adversely on disease outcomes in CD. Several studies have reported increased rates of intestinal surgery amongst smokers [6] [7] [8] [9] . Smoking may also impact upon other clinically important indices including disease flares, corticosteroid (CS) requirement and immuno-modulator use [10] [11] [12] , although a few small studies have found no association between tobacco exposure and poorer outcomes [13] [14] [15] .
The majority of previous studies examining the relationship between smoking and disease outcomes in CD have originated from secondary or tertiary care and are therefore likely to comprise of patients with a more severe phenotype. In a recent meta-analysis on the impact of smoking on disease outcomes in CD 32 of the 33 studies were derived from referral centres [16] . Population-based studies reporting on the relationship between smoking and disease course in CD are fewer in number [3, 13] , yet may be better placed to examine the true impact of smoking on outcomes in CD as they will include a more diverse range of patient phenotypes.
Smoking Status at diagnosis and Subsequent Smoking cessation: Associations With corticosteroid use and Intestinal resection in crohn's disease
Despite strong evidence that smoking is detrimental to gut health in CD, there is limited evidence that smoking cessation can improve disease outcomes [17, 18] . To our knowledge, the potential benefits of smoking cessation have not previously been evaluated in a population-based cohort that is free of referral centre bias.
We therefore aimed to perform a population-based study to investigate both the impact of smoking status at diagnosis and the impact of subsequent smoking cessation after diagnosis on clinical outcomes in CD. We hypothesised that smoking at the time of CD diagnosis is an independent risk factor associated with adverse outcomes in CD, and that smoking cessation would impact favourably.
MethodS

Data Source
We created a retrospective population-based incident cohort of all patients diagnosed with CD using the Clinical Practice Research Datalink (CPRD). CPRD is one of the largest and best validated primary care research databases in the world. Importantly, it is not an administrative dataset and thus is free from the biases inherent of such data sources. It contains longitudinal, patient-level, anonymised electronic health records from 674 general practices and is representative of around 8% of the United Kingdom (UK) population [19] . Primary care physicians use Read codes to record symptoms, signs, diagnoses, prescriptions, referrals and procedures including surgical operations. Data are rigorously audited to ensure a high level of accuracy and completeness. Participating practices need to achieve and maintain 'Up to standard' (UTS) status to continue contributing to the dataset. The database's primary purpose is for epidemiological research, and the coding system has been previously validated for use in inflammatory bowel disease (IBD) [20] . Numerous IBD-related studies have been undertaken using this data source [21] [22] [23] [24] . Furthermore, the CPRD has been used in a number of population-based studies, investigating both smoking habits and the impact of tobacco consumption on outcomes in other patient populations [25] [26] [27] . CPRD is well suited for this purpose and subsequent accuracy of recording of smoking status has been of high quality since its assessment became a key performance indicator for GPs in 2004 [28] .
We obtained ethical and scientific approval for the use of CPRD for our study from the Independent Scientific Advisory Committee (ISAC Protocol number: 15_018R).
Incident Case Definition and Cohort Construction
We have previously published detailed methodologies in defining incident cases of IBD from the CPRD [29] [30] [31] [32] [33] . In brief, to separate prevalent from incident cases of CD, we identified patients with a first Read code for CD at least 1 year after registering with a 'Up To Standard' practice for the period January 1st 2005 to December 31st 2014.
Patients were excluded if they had Read codes for both ulcerative colitis and CD, or indeterminate codes ('non-specific colitis' , 'colitis NOS' etc). Patients who had a co-morbid condition that might require regular or prolonged steroid use, for example, chronic asthma or polymyalgia rheumatica patients, were also excluded to avoid potential confounding. Patients with previous organ transplants were also excluded because of the likely use of concurrent immunosuppressant and steroid medications in this group. Patients were followed up from date of CD diagnosis until study endpoint, de-registration, or death.
Exposure Variable
Our main exposure variable was smoking status at CD diagnosis. Patients were defined as either 'smokers' or 'non-smokers' at the time of CD diagnosis based on Read codes for smoking status in the year before the first recorded CD diagnosis. 'Non-smokers' at CD diagnosis included patients who were either ex-smokers of at least one year, or 'never smokers' , as defined by Read codes (see additional online material). Where patients had contradicting or multiple codes for smoking status in the preceding year, the smoking code closest to the date of CD diagnosis was used. Completeness of smoking data within our dataset was approximately 80% (Fig. 1) . Accuracy of smoking status recording in CPRD has been demonstrated to be within 1% of self-reported smoking habits in national surveys [34] . Since April 2004, financial incentives in primary care were introduced for GPs to offer smoking cessation advice to patients aged over 16 years via the UK Quality and Outcomes Framework (QOF) scheme. This has substantially increased completeness of recording of smoking status [28] . We therefore chose a start for the study of January 1st 2005, 9 months after implementation of this scheme.
For the secondary analysis, we identified patients with further Read codes for smoking status in the first two years after CD diagnosis. Patients were considered 'persistent smokers' if they were smokers at CD diagnosis (as defined above) and had at least one further Read code indicating a smoking status within 2 years after diagnosis. Patients were labelled as 'quitters' if they were smokers at CD diagnosis, but had at least one subsequent Read code indicating they were non-smokers or ex-smokers in the two years following CD diagnosis.
Outcome Measures
Our primary outcome measure was oral CS use as a proxy measure of a CS-requiring disease flare-up ('CS-flare'), indicative of an exacerbation of CD. We derived three measures of CS use. Firstly we calculated the proportion of patients 'ever exposed' or 'never exposed' to oral CS. Patients were identified as 'ever exposed' if they had at least one prescription for oral CS during follow-up.
Secondly, we used a previously published methodology described by Grainge et al. [35] to define the number of 'CS flares' during follow-up. The first 'CS-flare' was defined as the first CS prescription registered in the patient record after date of CD diagnosis. The next separate 'CS-flare' was defined where a subsequent CS prescription was recorded following a period of at least 4 months without a CS prescription. This methodology allowed for the determination of total 'CS-flares' for the entire period of follow-up for each patient. Thus, the total number of 'CS-flares' was divided by follow-up time to generate the outcome measure 'CS-flares per year' .
Thirdly, we identified patients with steroid-dependency (defined as prolonged or repeated CS exposure) adapted from the European Crohn's and Colitis Organisation guidelines criteria [36] . A patient was defined as 'CS-dependent' if they had either a prescription for CS that lasted longer than 3 months, or required a repeat CS prescription within 3 months of stopping the previous CS course. CS dependency has been shown to be associated with poorer outcomes in patients with CD [37] .
Our secondary outcome measure was first intestinal surgery. This was defined as the first intestinal surgical procedure coded for following diagnosis of CD, and was derived using Read/OXMIS codes for intestinal surgery as previously described [29, 31] .
Covariates
We included a number of covariates with known or likely associations with poorer clinical outcomes in CD. These included: age at diagnosis, body mass index (BMI), social deprivation, severity of CD, concurrent 5-aminosalicylic acid (5ASA) or thiopurine use, and co-morbid conditions. Age at diagnosis has previously been shown to be relevant to surgical outcomes in the context of smoking status [3] . Patients were sub-divided into age categories at diagnosis of CD according to the Montreal Classification (A1: age less than 17 years, A2: 17 years to 40 years, A3: age greater than 40 at initial CD diagnosis). We also extracted data for BMI at diag- . BMI may be associated with risk of surgery in CD [38] . We used a surrogate marker for postcode-linked social deprivation, the index of multiple deprivation (IMD) to stratify patients by socio-economic status. Patients were categorised into IMD quintiles, where IMD category 1 represents the least deprived, and IMD category 5 represents the most socio-economically deprived. In the UK, people living in the areas of highest deprivation are more than twice as likely to smoke compared to the lowest [39] . We also identified patients with co-morbid irritable bowel syndrome (IBS) and depression. IBS is common in patients with IBD and may be confused with the symptoms of an IBD flare [40] . Furthermore, smoking is highly correlated with depressive illnesses [41] . We defined these co-morbidities to include any patient with a concurrent Read code for either IBS or a depressive diagnosis during the follow-up period.
We also extracted data for IBD medication usage other than CS. Patients were defined as 5-aminosalicylic acid (5ASA) users if they had one of more prescriptions during follow-up. Similarly, patients were defined as thiopurine (TP) users if they had one or more prescriptions for azathioprine (AZA) or 6-mercaptopurine (6MP) during follow-up. Prescription data for anti-tumour necrosis factor (aTNF) use is not reliably recorded in CPRD. We classified disease severity using a modification of the Beaugerie Index of severity [42] . This is a validated 4-point score calculated using three clinical variables that predict a 'disabling' disease course in CD, including a higher risk of IBD medication use, hospitalisation and surgery. The three variables are: age of CD onset < 40 years, early use of CS, defined in our population as a first CS prescription within 3 months of CD diagnosis, and lastly the presence of peri-anal disease, defined for the purpose of this study by codes for peri-anal surgery, as previously described [32] . A patient may have a score between zero (none of the variables) and 3 (all three variables). A score of 2 or more is associated with a positive predictive value of over 90% for 'disabling' disease [42] .
The 10-year study period was divided into five 2-year era to allow for assessment of the impact of era of CD diagnosis on outcome measures (era 1: 1/1/05 to 31/12/06, era 2: 01/1/07 to 31/12/08, era 3: 01/1/09 to 31/12/10, era 4: 01/1/11 to 31/1/12, era 5: 01/1/13 to 31/12/14).
Statistical Analysis
We used t-tests to determine differences between groups of continuous data, and Chi-squared or Fisher's exact test for comparisons of categorical data. We compared the proportion of smokers versus non-smokers at CD diagnosis who had any CS exposure, the number of CS flares per year in each group, and the proportion of patients with steroid dependency.
We used Kaplan-Meier analysis to generate survival curves calculating the time to first oral CS prescription in smokers and non-smokers. For both smokers and non-smokers, we calculated cumulative oral CS exposure rates in the follow-up period. The rate of oral CS exposure was determined as a function of time, by calculating the duration between diagnosis of CD and first oral CS prescription, or end of follow-up as defined above. The risk of oral CS use at 1, 3 and 5 years after CD diagnosis was also calculated. We used the log rank test to assess for any significant differences between smokers and non-smokers. We used the same statistical methodology to calculate the 1, 3 and 5 year risk of first intestinal surgery between smokers and non-smokers.
In a further analysis, we used separate Cox proportional hazards models to calculate hazard ratios (HR) for first intestinal surgery given smoking status at CD diagnosis. All available variables included in the univariate and multivariate analysis. Within this model we adjusted for sex, Montreal age category, BMI, era of CD diagnosis, IMD status (dichotomous variable-upper two IMD quintiles versus lower three quintiles), co-morbid depression, concurrent IBS, 5ASA and TP use, and disease severity (Beaugerie index score of greater than or equal to 2).
In the analysis comparing 'quitters' versus 'persistent smokers' , we used similar outcome measures as for the primary analysis. CS flare rate, CS dependency and IR rates were compared between these two sub-groups using Student's t-test, Chi squared test, and KM survival analysis with the log rank test.
A p value of less than or equal to 0.05 was considered statistically significant. All analyses were performed using STATA 12 (Statacorp LP, College Station, TX, USA).
reSultS
We identified 3553 patients with a new diagnosis of CD with 14,806 person years of follow-up between January 1st 2005 and December 31st 2014 (Fig. 1) . Of all, 1121 of 3553 patients (31.6%) were smokers at CD diagnosis. The difference in follow-up time between smokers (n = 1121) and non smokers (n = 2432) was not significant (4.3 years versus 4.1 years, p = 0.22). The overall proportion of smokers at diagnosis across the five era remained constant. However, the proportion of smokers at CD diagnosis aged 17-40 (Montreal A2 category) dropped from 37.4% in years 2005-6 (era 1) to 30.5% in years 2013-14 (era 5, Fig. 2) .
At baseline, there was no difference in the proportion of smokers and non-smokers aged 17-40 years (Montreal A2) and aged > 40 years (Montreal A3), respectively. There were significantly more non-smokers than smokers in the youngest age cohort ( Table 1) .
Amongst patients with CD, smokers were more likely to be female, live in deprived areas, and have a concurrent diagnosis of depression ( Table 1) . No differences between smokers and non-smokers were observed in the other baseline characteristics including BMI at diagnosis, IBS prevalence or disease severity. Nor were there any significant differences in 5-ASA use (52.1% versus 54.5%) and thiopurine use (35.5% versus 32.4%) during follow-up between smokers and non-smokers, respectively.
CS Use
Smokers had more overall exposure to oral CS therapy. Crude oral CS exposure was 55.8% in smokers versus 47.0% in non-smokers (p < 0.0001). Smokers were less likely to have CS-free remission, defined as no 'CS-flares' in follow-up. Smokers also had significantly more 'CS (requiring) flares' per year when compared with non-smokers ( Table 2) . Similarly, a higher proportion of smokers developed CS dependency than non-smokers (27.4 versus 20.8%, p < 0.0001).
The cumulative risk of oral CS use at 1, 3 and 5 years was 41.1%, 50.9% and 57.5% in smokers, and 34.9%, 43.0% and 49.0% in nonsmokers (log rank test for trend, p = 0.0001, see Fig. 3 ).
Intestinal Surgery
The crude rates for first intestinal surgery in patients with CD were 10.0 and 6.6% in smokers and non-smokers (p < 0.0001). The cumulative risk of first intestinal surgery at 1, 3 and 5 years was 5.3, 8.5 and 9.3% in smokers and 3.6, 5.1 and 6.7% in nonsmokers at CD diagnosis (log rank test for trend, p = 0.009, see Fig. 4) . Smoking was associated with a 64% increase in risk of first intestinal surgery (HR 1.64, 95% CI 1.16-2.52-see Table 3 ).
Impact of Smoking Cessation on Outcomes in CD
We identified 749 patients who were smokers at CD diagnosis who had subsequent Read codes for smoking status within the 
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The proportion of female 'persistent smokers' was significantly higher than male patients (66.8 versus 33.2%, p = 0.001). There was also significant differences in the proportions of 'persistent smokers' between the Montreal age groups (A2 50.1%, A3 59.8%, p = 0.008). Similarly, 'persistent smokers' were more likely to have co-existent depression than 'quitters' (19.0 versus 11.6%, p = 0.0001). There were no differences between 'persistent smokers' and 'quitters' with respect to BMI or IMD categories, or the proportion of patients with co-existent IBS.
'Quitters' had lower overall CS use. Crude oral CS exposure was 53.7% in 'quitters' versus 61.3 in 'persistent smokers' (p = 0.03). Mean number of CS flares per year was 0.61 in 'quitters' versus 1.20 in 'persistent smokers' , although this difference did not reach statistical significance. However, the proportion of 'quitters' who maintained steroid-free remission during follow-up was significantly higher than amongst 'persistent smokers' (45.4 versus 37.5%, p = 0.02). Furthermore, there was a significantly higher proportion of 'persistent smokers' who developed CS dependency compared to the 'quitters' (32.8% in 'persistent smokers' versus 23.9% amongst 'quitters'-see Fig. 5 ).
Crude IR rates were 10.2% in 'quitters' and 11.5% in 'persistent smokers (p = 0.54). The 1, 3 and 5 year cumulative risk of IR was 5.6, 7.9 and 10.3% in 'quitters' and 5.5, 10.4 and 12.1% in 'persistent smokers' , although the differences did not reach statistical significance (see Fig. 6 ).
The marked difference in co-morbid depression prevalence between 'quitters' and 'persistent smokers' was explored given the potential independent effect of depression on outcomes in IBD [43] . In multiple logistic regression analysis adjusting for age, sex, obesity and social deprivation, depression was associated with an 84% increased odds of being a 'persistent smoker' (OR 1.84, 95% CI 1.04-3.25, p = 0.04). However, amongst our CD cohort, the presence of depression did not impact on the key outcomes of CS dependency and intestinal resection (IR) proportionally when comparing quitters and persistent smokers with/without depression. There were no statistical differences in the proportion of patients developing CS dependency between 'persistent smokers' with or without depression (35.4 versus 32.5%, p = 0.56), or 'quitters' with or without depression (30.8 versus 23.0%, p = 0.28). Similarly, there were no statistical differences in the proportion of CD patients who underwent intestinal surgery between 'persistent smokers' with or without depression (17.7 versus 10.1%, p = 0.06), or 'quitters' with or without depression (2.6 versus 11.2%, p = 0.10).
dIScuSSIon
Main Findings
This is the is the first population-based study to report on the impact of smoking cessation on clinical outcomes in CD. Smoking at diagnosis was associated with both an increase in CS-requiring flares, the development of CS dependency and risk of IR. Smoking cessation within the first 2 years of diagnosis was associated with a reduction in CS dependency by almost a quarter compared to persistent smokers. The proportion of quitters in steroid-free remission during follow-up was almost a fifth higher than in persistent smokers. Rates of intestinal surgery amongst quitters were reduced but did not reach statistical significance.
Findings in Relationship to Other Studies
This study is the first to demonstrate the benefit of smoking cessation in a population-based cohort on the key clinical outcome of CS dependency. In a landmark study by Cosnes et al., CD patients from a tertiary centre who continued to smoke, when compared to those who had quit or had never smoked, had higher rates of disease flares, steroid use and immunosuppressant use, although surgical rates remained unaffected [17] . More recently, a prospective observational study by Nunes et al. including 573 patients with CD from 14 IBD referral centres in Spain reported similar findings [18] . Our study is the first to address the impact of smoking on CS dependency as specifically defined by ECCO guidelines [44] . Reducing CS dependency is an important goal in IBD management given the long-term clinical side effects and adverse outcomes associated with CS dependency in IBD [45] . Our findings are in keeping with other referral centre studies that have demonstrated that smoking is associated with increased CS use [10] [11] [12] , increased disease activity or disease flares [6, 13] , and progression from an inflammatory to a stricturing or penetrating disease pattern that often requires surgery [46] . A recent meta-analysis that included nine studies of patients with CD, found a 56% increased risk of disease flare in patients who smoked (pooled odds ratio 1.56, 95% CI 1.21-2.01) [16] .
We did not find any statistical difference in risk of TP exposure in between smokers and non-smokers, although the results approached statistical significance (35.5 versus 32.4% in smokers and non-smokers respectively, p = 0.06). Similar findings have also been reported in a study by Seksik et al., [6] in which immunomodulator (IM) use did not vary between non-smokers, light smokers and heavy smokers. By contrast, other studies have demonstrated increased IM use amongst smokers with CD [10] [11] [12] . Interestingly, in a retrospective analysis of steroid-dependent IBD patients, including 103 CD patients treated with thiopurines, there was no difference in steroid-free remission between smokers and non-smokers [47] . We found a significantly higher risk of first intestinal surgery amongst CD patients who smoked at diagnosis (HR 1.64, 95% CI 1.06-2.52). Our findings add to the body of evidence base that suggest an increased risk of intestinal surgery amongst smokers [6, 9, 48] . The majority of studies in this field have been derived from data collected in secondary care. One previous study by Frolkis et al. reported population-based data on the impact of smoking on risk of surgery in CD using The Health Improvement Network (THIN), although it did not evaluate the impact of smoking cessation in this cohort. THIN is a UK primary care database that shares information from some practices within CPRD and also includes patient data from practices that do not contribute to CPRD, although is smaller in size than CPRD. This study included 1500 CD patients and reported that current smoking at time of CD diagnosis was associated with a threefold increase in risk of intestinal surgery (HR 2.99, 95% CI 1.52-5.92), although this increased risk was only apparent in patients diagnosed with CD over the age of 40 years (Montreal A3) [3] . This contrasts with our own larger study that found no age-related differences in multi-variate analysis, which may reflect the size of our cohort, differences in adjusting for confounding, and minor variations in the definitions of smoking at CD diagnosis.
Smoking rates in the UK as in many developed countries have fallen since legislation banning smoking in public spaces were introduced, and our cohorts show similar trends in smoking prevalence. Data from the Global Burden of Disease (GBD) tobacco collaborators study reported an annual percentage drop in smoking prevalence of 0.9-1.2 between 2005-15 [2] . During our 10-year study period, there was a sustained and significant decrease in proportion of patients aged 17-40 years (Montreal A2) who were smokers at diagnosis from 37.4 to 30.5%, or a drop of approximately 0.7%/year. Research on smoking cessation in the UK general population has also shown a differential rate of smoking cessation, with the highest quit rates amongst 21-30 year olds [49] . This is against a background of an overall drop in smoking prevalence in UK adults from 46% in 1974 to 19% in 2014 [50] . The drop in smokers at diagnosis may also reflect changing smoking habits in the wake of the UK smoking ban that was introduced in July 2007 [51] , in addition to the introduction of QOF targets in UK general practices [28] . In a sensitivity analysis of our own data, we found the proportion of CD patients aged 17-40 years (Montreal A2) who smoked at diagnosis dropped significantly from 37% in the pre-smoking ban era to 30% in the post-smoking ban era, whereas there were no changes in the other age categories.
That smoking worsens, and conversely cessation improves disease course in CD, can be explained by a host of biological, clinical and social factors. Tobacco smoke is postulated to cause inflammation and damage to the gastrointestinal tract via a number of mechanisms [52] . Smoking may lead to alterations in the intestinal flora in patients with IBD manifest as decreased species diversity and reduced anti-inflammatory phyla, for example Firmicutes [53] . Smoking in CD may also increase potentially pro-inflammatory Bacteioroides species [54] . Constituents of tobacco smoke may inhibit anti-inflammatory pathways, dysregulate monocyte function and alter small bowel permeability [55] [56] [57] .
Smoking may also impact on the efficacy of CD-specific medication. Smokers are more likely to discontinue thiopurine therapy because of side effects [47] . Smoking has also been suggested to reduce the effectiveness of biologic therapies, but this association remains unconfirmed [58] . Furthermore, reports from some non-IBD populations indicate medication adherence amongst smokers may be worse [59] .
Strengths and Limitations
This is the first population-based study investigating the impact of smoking cessation on disease outcomes in patients with CD. Data were drawn from a large nationally representative validated research database free of referral centre bias. CPRD has previously been validated as a tool to study IBD, including smoking exposure [20, 60] . Completeness for the recording of smoking status is reported at over 98% in some patient populations [28] . In our regression model we have accounted for multiple demographic and clinical covariates that add strength to our findings.
We acknowledge certain limitations to our study. A potential limitation is that longitudinal data with regard to smoking continuation and cessation were incomplete, and reduced the size of the cohort available for analysis of the impact of smoking cessation. However to date this is the only population-based study to evaluate the impact of smoking cessation in CD. Furthermore, our measure of smoking status may have been subject to recall bias by patients or a failure of clinicians to inquire about and record status accurately [4] . This could potentially result in an underestimation of any effect. Furthermore, our study did not account for smoking intensity or alternative types of tobacco exposure.
With respect to the smoking cessation analysis, we evaluated the impact of cessation with in the first 2 years of diagnosis. We classified the status of quitting or smoking persistence based on changes in smoking codes within the first 2 years after CD diagnosis. Our methodology defines cessation based on an event documented and coded for by the primary care physician and not the actual date the patient stopped smoking. It is possible therefore that CS use and IR may have occurred before the actual 'quit date' . Reassuringly in this respect we found in a sensitivity analysis that mean time to a change in smoking code (227 days from CD diagnosis) was significantly shorter than the mean time to either CS dependency We also acknowledge CPRD contains limited information about disease phenotype, activity, severity and endoscopic data, but emphasise that this database has been validated for use in IBD-related research [20] . We have however attempted to adjust for some of these restrictions, including developing surrogate markers for disease activity to generate 'CS-flare' data using a previously published methodology [35] . We also recognise the potential limitations of using CS prescription data to define disease activity rather than objective markers. Nevertheless this does often reflect 'real world' clinical practice. Our methodology will also fail to capture patients who choose against taking steroids for a flare, although postulate this would be a small proportion of patients.
We were however able to control for disease severity using the validated Beaugerie index [42] . Additionally, we used a previously described comprehensive list of Read codes to determine whether a patient had intestinal surgery [29] . We accept some patients, in particular those in the older (A3) age group, may have undergone surgery for indications other than CD, such as cancer. The associated impact of smoking status on IBD-specific hospitalisation would also have been of interest but CPRD does not code for this parameter.
CPRD contains limited data on aTNF medications, since these treatments are usually prescribed in secondary care and thus is a potential confounder. It is noteworthy that in 2006, only an estimated 3% of the British CD population was on biologic therapy [61] , but has steadily risen since [62] . In our multivariate analysis we have shown that era of diagnosis was not a significant covariate implying that changes in biologic use between the era did not impact significantly on the measured outcomes. This is also consistent with a recent Spanish registry study, which reported that smoking was associated with a more deleterious disease course irrespective of increased biologic use [11] .
Implications
Our results support the hypothesis that intestinal inflammation is exacerbated by tobacco exposure in CD and worsens subsequent clinical outcomes, notably steroid use and requirement for intestinal surgery. Importantly it supports the notion that smoking cessation has a favourable impact.
Smoking is the only truly modifiable risk factor in disease course in CD and our findings underscore the importance of assessing smoking status at first presentation, and counselling patients who smoke that continued tobacco use is likely to be associated with detrimental outcomes, but that quitting smoking will improve their disease course. This is particularly pertinent given patient knowledge as to the potentially negative impact of smoking on outcomes in IBD may be lacking [63, 64] . We recommend that smoking cessation strategies should be prioritised in systematic shared care protocols bridging primary and secondary care since there is good evidence, that when clinicians support patients, about a third will quit [65] , with resultant improvement in clinical outcomes in those that achieve this goal [18] . There may be added value in focusing this effort on certain target populations, including younger patients or light smokers who are more likely to succeed with complete cessation [66] . There may also be considerable economic benefits to healthcare services employing cessation programs in CD [67] .
Further work is needed to quantify the effect of smoking exposure ideally using objective markers that are not subject to recall bias such as salivary cotinine [68] . Additionally, future prospective studies that quantify smoking exposure by accurately recording smoking intensity (number of cigarettes smoked per day), could be used to investigate the potential of a tobacco 'dose effect' . 6 kM curves showing probability of first intestinal surgery in patients with crohn's disease: 'quitters' versus 'persistent smokers.' Quitters-cd patients who were smokers at diagnosis but had subsequent read codes in the 2 years following diagnosis, indicating they were ex or non-smokers Persistent smokers-cd patients who were smokers at diagnosis and had subsequent read codes in the 2 years following diagnosis, indicating they were still smokers
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